This co-development deal announced between BMS (maker of Opdivo (nivolumab)) and Five Prime Therapeutics is a PD-1 combo trial I am watching closely & crossing fingers for MSS CRC. It combines a PD-1 inhibitor with a drug called FPA008 which blocks something called CSF1R. http://www.businesswire.com/news/home/2 ... h9lf75Aw20
Scientists hope that blocking CSF1R would remove immunosupression from the "tumor microenvironment" - and make "cold tumors" (e.g. MSS-CRC tumors are "cold") more "hot" i.e. able to be attacked by the immune system. This is a subject I wrote about in a general way here: http://fightcolorectalcancer.org/resear ... ot-part-1/
Here is the link to the Phase 1 trial. As far as I know it is open to both MSI and MSS CRC patients. It just started in TX - they are planning a big trial so I am sure multiple additional sites will be opening soon.https://clinicaltrials.gov/ct2/show/NCT ... 008&rank=1
This is a Phase 1 trial so no clinical data that it works yet - but from a purely scientific point of view, I think worthy of keeping a very close eye on!
Last edited by DK37
on Sat Oct 17, 2015 9:28 am, edited 1 time in total.
6/4/2012 Dx Stage 3C CRC @ 40 yo. MSS, KRAS-WT, BRAF-WT, p53-mut
8/13 Enlarged lymphs - Stable
10/14 Stage IV. Lung & Lymph mets. 5-FU+bev
11/15 FOLFIRI + bev
11/16 Signs of FOLFIRI resistance (Lymph mets)
1/17 Palliative radiation for resistant mets
2/17 FOLFIRI + bev + Maraviroc (off-label)
3/17 FOLFIRI + Erbitux + Maraviroc (off-label)MSS-CRC Clinical Trial Finder: http://trialfinder.fightcrc.org/2016 Colondar 2.0 ModelDK37 Science Posts List